Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Hypertension Reports
Published in: Current Hypertension Reports 3/2015

01-03-2015 | Secondary Hypertension: Nervous System Mechanisms (J Bisognano, Section Editor)

The Baroreflex in Hypertension

Authors: Genaro Fernandez, Junsoo Alex Lee, Lynn C. Liu, John P. Gassler

Published in: Current Hypertension Reports | Issue 3/2015

Login to get access

Abstract

Hypertension is a complex syndrome that increases the risk of developing other medical comorbidities and interacts with other medical conditions to increase the risk of target end-organ damage such as cardiovascular disease, stroke, and renal disease. Hypertension remains under-recognized and poorly controlled in the USA and worldwide. In some patients, hypertension is resistant to optimal medical therapy. Over the last few decades, there has been an increasing understanding of the role of the sympathetic nervous system in the development and maintenance of hypertension. This update reviews the physiology and role of the sympathetic nervous system in hypertension and pharmacological and interventional treatments directed at nervous system involvement in secondary hypertension.
Literature
1.
Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;364:217–23.CrossRef
2.•
Carey RM. Resistant hypertension. Hypertension. 2013;61:746. This article provides a clear definition of what true resistant hypertension involves. It describes its prevalence and the various potential treatments including medications and interventional treatments. It also describes some of the pitfalls such as inadequate dosing regimens, inappropriate pharmacological combinations, and lack of treatment intensification or medication adherence as reasons for why hypertension is difficult to control.CrossRefPubMed
3.
Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2009;51:1403–19.CrossRef
4.
Fisher JP, Young CN, Fadel PJ. Central sympathetic overactivity: maladies and mechanisms. Autonm Neurosci. 2009;148:5–15.CrossRef
5.•
Lovic D, Manolis AJ, et al. The pathophysiological basis of carotid baroreceptor stimulation for the treatment of resistant hypertension. Curr Vasc Pharmacol. 2014;12:16–22. This article describes physiology of blood pressure regulation, specifically role carotid baroreceptors. It provides a summary of animal and human studies on long-term effect of baroreceptors on hypertension.CrossRefPubMed
6.
Drummond HA, Price MP, Welsh MJ, et al. A molecular component of the arterial baroreceptor mechanotransducer. Neuron. 1998;21:1435–41.CrossRefPubMed
7.
Lovic D, Manolis AJ, et al. The pathophysiological basis of carotid baroreceptor stimulation for the treatment of resistant hypertension. Curr Vasc Pharmacol. 2014;12:16–22.CrossRefPubMed
8.
Dampney RA. Functional organization of central pathways regulating the cardiovascular system. Physiol Rev. 1994;74:323–264.PubMed
9.
McCubbin JW, Green JH, Page IH. Baroreceptor function in chronic renal hypertension. Circulation Res. 1956;4:205–10.CrossRefPubMed
10.
Matton G. Carotid sinus and neurogenic and renal hypertension. J Physiol. 1954;126:13P–4P.
11.
Bishop VS, Haywood JR, Shade RE, et al. Aortic baroreceptor deafferentation in the baboon. J Appl Physiol. 1986;60:798–801.PubMed
12.
Schwartz SI, Grittith LS, Neistadt A, et al. Chronic carotid sinus nerve stimulation in the treatment of essential hypertension. Am J Surg. 1967;114:5–15.CrossRefPubMed
13.
Izzo JL, Sica DA and Black HR; (2008) ‘Renal sympathetic nerves and extracellular fluid volume regulation’. In: Hypertension primer. Philadelphia: Lippincott Williams and Wilkins.
14.
Cowley Jr AW, Liard JF, Guyton AC. Role of the baroreceptor reflex in daily control of arterial blood pressure and other variables in dogs. Circ Res. 1973;32:564–76.CrossRefPubMed
15.
16.
Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008;51:1403–19.CrossRefPubMed
17.
Persell SD. Prevalence of resistant hypertension in the United States, 2003–2008. Hypertension. 2011;57:1076–80.CrossRefPubMed
18.
Taler SJ, Textor SC, Augustine JE. Resistant hypertension: comparing hemodynamic management to specialist care. Hypertension. 2002;39:982–12.CrossRefPubMed
19.
Pimenta E, Gaddam KK, Oparis S, et al. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension. 2009;54:475–81.CrossRefPubMedCentralPubMed
20.
Furberg CD, Wright JT, Davis BR, et al. ALLHAT. JAMA. 2002;288(23):2981–97.CrossRef
21.
Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289(19):2560–72.CrossRefPubMed
22.•
James PA, Opari S, Carter BL, et al. Evidence-based guideline for the management of high blood pressure in adults. JAMA. 2014;311(5):507–20. This publication provides JNC8’s latest evidence-based recommendations for the management of hypertension. It makes nine recommendations that are based solely on randomized control trial data rather than on observational studies such as in JNC7 guidelines. Its main shift is that in those aged 60 and above, one should initiate pharmacologic treatment to lower systolic blood pressure of 150 mmHg or higher or diastolic BP of 90 mmHg or higher.CrossRefPubMed
23.
Douma S, Petidis K, Doumas M, et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet. 2008;371:1921–6.CrossRefPubMed
24.
Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008;51:1403–19.CrossRefPubMed
25.
Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens. 2003;16:925–30.CrossRefPubMed
26.
Ouzan J, Perault C, Lincoff AM, Carre E, Mertes M. The role of spironolactone in the treatment of patients with refractory hypertension. Am J Hypertens. 2002;15:333–9.CrossRefPubMed
27.•
Bhatt DL, Kandzari DE, O’Neill WW, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370:1392–401. This prospective, single-blind, randomized, sham-controlled study showed that there was a significant drop in ambulatory and office-based blood pressure with both patients with renal denervation and those with the sham procedure. However, there was no significant difference in systolic blood pressure reduction between the two groups after 6 months.CrossRef
28.
Nicholas AP, Hokfelt T, Pieribone VA. The distribution and significance of CNS adrenoceptors examined with in situ hybridization. Trends Pharmacol Sci. 1996;17:245–55.CrossRefPubMed
29.
Edwards LP, Brown-Bryan TA, Mclean L, et al. Pharmacological properties of the central antihypertensive agent. Moxonidine Cardiovasc Ther. 2012;30:199–208.CrossRef
30.
Furberg CD, Wright JT, Davis BR, et al. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981–97.CrossRef
31.
James PA, Opari S, Carter BL, et al. 2014 Evidence-based guideline for the management of high blood pressure in adults. JAMA. 2014;311(5):507–20.CrossRefPubMed
32.
Dahlof B, Devereux RB, Kjeldsen SE, LIFE Study Group, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet. 2002;359(9311):995–1003.CrossRefPubMed
33.
Hamilton WF, Richards DW. Ouput of the heart. In: Fishman AP, Richards DW, editors. Circulation of the blood. Men and ideas. Bethesda: American Physiological Society; 1982. p. 87–90.
34.
Adson AW, McCraig W, Brown GE. Surgery in its relation to hypertension. Surg Gynecol Obstet. 1936;62:314–31.
35.
Smithwick RH, Bush RD, Kinsey D, Whitelaw GP. Hypertension and associated cardiovascular disease: comparison of male and female mortality rates and their influence on selection of therapy. J Am Med Assoc. 1956;160:1023–6.CrossRefPubMed
36.
Illig KA, Levy M, Sanchez L, et al. An implantable carotid sinus stimulator for drug-resistant hypertension: surgical technique and short-term outcome from the multicenter phase II Rheos feasibility trial. J Vasc Surg. 2006;44:1213–8.CrossRefPubMed
37.
Schmidli J, Savolainen H, Eckstein F, et al. Acute device-based blood pressure reduction: electrical activation of the carotid baroreflex in patients undergoing elective carotid surgery. Vascular. 2007;15:63–9.CrossRefPubMed
38.
Scheffers IJM, Kroon AA, Schmidli J, et al. Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. J Am Coll Cardiol. 2010;56:1254–8.CrossRefPubMed
39.•
Bisognano JD, Bakris G, Nadim MK, et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension. J Am Coll Cardiol. 2011;58:765–73. This was the first large-scale randomized, double-blind, placebo-controlled device clinical trial that assessed the efficacy and safety of the Rheos baroreflex activation therapy (BAT) in patients with resistant hypertension via five prespecified coprimary endpoints. Though it did not meet short-term safety and short-term efficacy endpoints, it showed mean reductions in SBP of up to 35 mmHg at 12 months with over 50 % of patients achieving a SBP of <140 mmHg.CrossRefPubMed
40.•
Hoppe UC, Brandt MC, Wachter R, et al. Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial. J Am Soc Hypertens. 2012;6:270–6. This is a single-arm, open-label European study enrolled 30 patients with resistant hypertension to carotid baroreflex activation therapy. BAT caused a blood pressure reduction of 22.3 ± 9.8 mmHg. Its safety profile was comparable to pacemaker implantation.CrossRefPubMed
41.
DiBona GF, Esler M. Translational medicine: the antihypertensive effect of renal denervation. Am J Physiol Regul Integr Comp Physiol. 2010;298:R245–53.CrossRefPubMed
42.
Smithwick RH, Thompson JE. Splanchnicectomy for essential hypertension; results in 1266 patients. JAMA. 1953;152:1501–4.CrossRef
43.
Hinton JW, Lord JW. The surgical treatment of essential hypertension; a comparison of the results of the classical Smithwick operation and the extensive thoracolumbar sympathectomy. Surg Clin North Am. 1948;28(2):290–3.PubMed
44.
Grimson KS, Orgain ES, Anderson B, et al. Total thoracic and partial to lower lumbar sympathectomy and celiac ganglionectomy for hypertension. Ann Surg. 1953;152:1501–4.
45.
Schlaich MP, Sobodka PA, Krum H, et al. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med. 2009;361:932–4.CrossRefPubMed
46.
Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicenter safety and proof-of-principle cohort study. Lancet. 2009;373:1275–81.CrossRefPubMed
47.
Symplicity HTN-2 Investigators, Esler MD, Krum H, Sobodka PA, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomized controlled trial. Lancet. 2010;376:1903–9.CrossRef
48.•
Doumas M, Anyfanti P, Bakris G. Should ambulatory blood pressure monitoring be mandatory for future studies in resistant hypertension: a perspective. J Hypertens. 2012;30:874–6. This article questions whether we should focus on ambulatory blood pressure reduction rather than office blood pressure reduction. It reviews the big discrepancy between impressive office blood pressure reductions with conventional antihypertensive treatment or invasive methods with the more believable ambulatory blood pressure reduction. It raises the validity of office readings.CrossRefPubMed
49.
Bhatt DL, Kandzari DE, O’Neill WW, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370:1392–401.CrossRef
50.•
Fadl Elmula FE, Hoffmann P, Fossum E, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension after witnessed intake of medication before qualifying ambulatory blood pressure. Hypertension. 2013;62:526–32. This study emphasized the importance of drug adherence. Out of 18 patients referred to hypertension specialists for treatment of resistant hypertension by renal denervation, 12 were eliminated from the study including five who had normalization of blood pressure by being monitored while taking their blood pressure medications. It demonstrates that medication noncompliance is common and speculates whether renal denervation truly works or whether it helps by improving drug adherence.CrossRefPubMed
51.•
Fadl Elmula FE, Hoffman P, Larstorp AC, et al. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension. 2014;63:1–9. This small study with 19 patients looked at the blood pressure-lowering effect of renal sympathetic denervation versus clinically adjusted drug treatment in patients with confirmed resistant hypertension. It ruled out patients with medication noncompliance. At 6 months, systolic and diastolic blood pressure was lowered in the drug-adjusted group as compared to the renal denervation group.CrossRef
52.
Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med. 1999;341:577–85.CrossRefPubMed
53.
Chapleau MW. Arterial baroreflexes. Hypertension primer: the essential hypertension of high blood pressure, 4th edn. London: Lippincott Williams & Wilkins; 2008.
Metadata
Title
The Baroreflex in Hypertension
Authors
Genaro Fernandez
Junsoo Alex Lee
Lynn C. Liu
John P. Gassler
Publication date
01-03-2015
Publisher
Springer US
Published in
Current Hypertension Reports / Issue 3/2015
Print ISSN: 1522-6417
Electronic ISSN: 1534-3111
DOI
https://doi.org/10.1007/s11906-014-0531-z

Other articles of this Issue 3/2015

Current Hypertension Reports 3/2015 Go to the issue

Hypertension and Metabolic Syndrome (JR Sowers and A Whaley-Connell, Section Editors)

Natriuretic Peptides as a Novel Target in Resistant Hypertension

Hypertension and Metabolic Syndrome (JR Sowers and A Whaley-Connell, Section Editors)

Understanding the Importance of Race/Ethnicity in the Care of the Hypertensive Patient

Secondary Hypertension: Nervous System Mechanisms (J Bisognano, Section Editor)

Renal Denervation in Heart Failure

Hypertension and Metabolic Syndrome (JR Sowers and A Whaley-Connell, Section Editors)

Visit-to-Visit Variability of Systolic Blood Pressure and Cardiovascular Disease

Antihypertensive Agents: Mechanisms of Drug Action (ME Ernst, Section Editor)

Thiazide Diuretics in Chronic Kidney Disease

Hypertension and Metabolic Syndrome (JR Sowers and A Whaley-Connell, Section Editors)

The Western Diet and Chronic Kidney Disease
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits